Percheron Therapeutics Limited (ASX: PER) - Share Price

Current share price for PER : $0.004 0.001 (33.33%)⁺

Percheron Therapeutics Limited (PER, formerly Antisense Therapeutics Limited) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA.

PER General Information ⁺

ASX Code	PER
Website	N/A
Industry/Sector	Pharmaceuticals
Market Cap ($M)	6
PER Share Price	$0.004
Day High	$0.005
Day Low	$0.003
Last Close	$0.003
PER Share Price Movement	$0.00 ( 33.33% )

Prices as at 16:40, 10 Aug 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Percheron Therapeutics Limited (PER) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Percheron Therapeutics Limited (PER) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Percheron Therapeutics Limited (PER) price-sensitive announcements

PER - Quarterly Activities Report and Appendix 4C

Percheron Therapeutics Limited, an Australian biotechnology company, provided an update on

Percheron Therapeutics Limited (PER)
31 Jul 2026 | 8:29 AM

PER - Quarterly Activities Report and Appendix 4C

Percheron Therapeutics Limited, a biotechnology company focused on novel therapies for onc

Percheron Therapeutics Limited (PER)
30 Apr 2026 | 8:57 AM

PER - Results of Entitlement Offer

Percheron Therapeutics Limited announced the completion of its Entitlement Offer, raising

Percheron Therapeutics Limited (PER)
14 Apr 2026 | 1:00 PM

PER - Prospectus - Non-renounceable Entitlement Offer

Percheron Therapeutics Limited's prospectus announces a non-renounceable entitlement offer

Percheron Therapeutics Limited (PER)
16 Mar 2026 | 10:01 AM

Percheron Therapeutics Limited (PER) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Percheron Therapeutics Limited (PER) ORDINARY FULLY PAID	Health Care	$6	Percheron Therapeutics Announces CEO Succession	10 Aug 2026 8:24AM	$0.003	$0.004	risen by 33.33%
Percheron Therapeutics Limited (PER) ORDINARY FULLY PAID	Health Care	$6	Quarterly Activities Report and Appendix 4C	31 Jul 2026 8:29AM	$0.003	$0.004	risen by 33.33%
Percheron Therapeutics Limited (PER) ORDINARY FULLY PAID	Health Care	$6	Notification regarding unquoted securities - PER	3 Jul 2026 4:21PM	$0.004	$0.004	risen by 14.29%
Percheron Therapeutics Limited (PER) ORDINARY FULLY PAID	Health Care	$6	Completion of HMBD-002 Drug Substance Manufacture	17 Jun 2026 8:22AM	$0.005	$0.004	fallen by 11.11%
Percheron Therapeutics Limited (PER) ORDINARY FULLY PAID	Health Care	$6	New HMBD-002 Data Presented at ASCO Annual Meeting	2 Jun 2026 8:22AM	$0.005	$0.004	fallen by 11.11%
Percheron Therapeutics Limited (PER) ORDINARY FULLY PAID	Health Care	$6	Notification regarding unquoted securities - PER	1 Jun 2026 3:41PM	$0.005	$0.004	fallen by 11.11%

PER Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2027F	C2	-$0.50	23.70%	0.00%	0.0%
2026F	C2	-$0.40	-72.70%	0.00%	0.0%
2025A	-$14.92	-$1.40	7.80%	0.00%	0.0%

PER Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2025 A	2026 F	2027 F	2025 A	2026 F	2027 F	2025 A	2026 F	2027 F
Clarity Pharmaceuticals Ltd (CU6)	$1,000M	0.3002	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Neuren Pharmaceuticals Limited (NEU)	$2,733M	-0.7857	0.2462	0.9655	92.6515	74.3448	37.8246	0.00%	0.00%	0.00%
Percheron Therapeutics Limited (PER)	$5M	0.0775	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%

PER Directors

Name	Position	Start Date
Dr James Garner	Chief Executive Officer, Managing Director	8 May 2023
Dr Charmaine Hilary Gittleson	Executive Chairman, Executive Director	22 Mar 2021
Dr Ben Gil Price	Non-Executive Director	4 Oct 2021

Percheron Therapeutics Limited (PER) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
15 Apr 2026	GARNER, James	Issued	Direct Shares	21,400,000	$0.005	$107,000.000
22 Dec 2025	PRICE, Ben	Buy	Direct Shares	2,000,000	$0.009	$17,220.060
19 Dec 2025	GARNER, James	Buy	Direct Shares	1,000,000	$0.009	$8,500.000

See all changes in directors' interest & trades for Percheron Therapeutics Limited (PER) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

PER Management

Name	Position
Deborah Ambrosini	Chief Financial Officer,Company Secretary

PER Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Percheron Therapeutics Limited (PER). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
59,199,300 (5.44%)	Mutual Investments Pty Ltd

PER Calendar of Events

Date	Event
25 February 2027	Report (Interim)
27 August 2026	Report (Annual)
27 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us